1Guidelines sub-committee. 2003 guidelline for the management of mild hypertension: memorandum from a Word Health Organlzation/lnternational Society of Hypertemsion meet [ J ]. J Hypertension, 2003,21 : 1011
4[1]THRMANN PA. Angiotensin II antagonism and the heart: valsartan in left ven tricular hypertrophy [J]. J Cardiovasc Pharmacol ,1999, 33 Suppl 1:S33-S36.
5[2]PLUM J, BNTEN B, N**METH R, et al. Effects of the angiotensin II ant agonist valsartan on blood pressure, proteinuria, and renal hemodynamics in patients wit h chronic renal failure and hypertension [J]. J Am Soc Nephrol, 1998, 9(12): 2 223-2234.
6[3]BREMNER AD, BAUR M, ODDOU-STOCK P, et al. Valsartan: long term effica cy and tolerability compared to lisinopril in elderly patients with essential hypertens ion [J]. Clin Exp Hypertens, 1997, 19(8): 1263-1285.
7[4]MARKHAM A, GOA KL. Valsartan a review of its pharmacology and therapeutic use in essential hypertension [J]. Drugs ,1997 ,54(2): 299-311.
8[5]BLACK HR, GRAFF A, SHUTE D, et al. Valsartan, a new angiotensin II ant agonis t for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril [J]. J Hu m Hypertens, 1997,11(8): 483-489.